- Report
- October 2024
- 198 Pages
Global
From €3399EUR$3,545USD£2,840GBP
€3776EUR$3,939USD£3,155GBP
- Report
- April 2025
- 50 Pages
Global
From €2540EUR$2,650USD£2,123GBP
- Report
- February 2025
- 200 Pages
Global
From €4304EUR$4,490USD£3,597GBP
- Report
- May 2024
- 133 Pages
Global
From €6230EUR$6,499USD£5,206GBP
Eptifibatide is a cardiovascular drug used to treat acute coronary syndrome (ACS). It is a glycoprotein IIb/IIIa inhibitor, which works by blocking the action of platelets in the blood, preventing them from forming clots. It is administered intravenously and is usually used in combination with other drugs such as aspirin and heparin. Eptifibatide is used to reduce the risk of death, heart attack, and stroke in patients with ACS. It is also used to reduce the risk of recurrent ischemic events in patients with unstable angina or non-ST-segment elevation myocardial infarction.
Eptifibatide is available in the market as a generic drug and is also sold under the brand names Integrilin and Reopro. It is manufactured by several pharmaceutical companies, including Merck, Pfizer, and Bristol-Myers Squibb. Show Less Read more